


































The Effects of Beetroot Juice on Blood Pressure, Microvascular Function
and Large-Vessel Endothelial Function: A Randomized, Double-Blind,
Placebo-Controlled Pilot Study in Healthy Older Adults.






Publisher's PDF, also known as Version of record
Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Jones, T., Dunn, E., Macdonald, J., Kubis, H-P., McMahon, N., & Sandoo, A. (2019). The Effects
of Beetroot Juice on Blood Pressure, Microvascular Function and Large-Vessel Endothelial
Function: A Randomized, Double-Blind, Placebo-Controlled Pilot Study in Healthy Older Adults.
Nutrients, 11(8), 1792. https://doi.org/10.3390/nu11081792.
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.
 11. May. 2021
nutrients
Article
The Effects of Beetroot Juice on Blood Pressure,
Microvascular Function and Large-Vessel
Endothelial Function: A Randomized,
Double-Blind, Placebo-Controlled Pilot
Study in Healthy Older Adults
Tomos Jones 1,*, Emily Louise Dunn 1, Jamie Hugo Macdonald 1, Hans-Peter Kubis 1,
Nicholas McMahon 2 and Aamer Sandoo 1
1 School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd,
Wales LL57 2PZ, UK
2 School of Human Movement and Nutrition Sciences, University of Queensland,
St. Lucia, QLD 4067, Australia
* Correspondence: tomos.jones@bangor.ac.uk; Tel.: +012-483-88-147
Received: 18 June 2019; Accepted: 30 July 2019; Published: 2 August 2019


Abstract: Dietary nitrate (NO3−) has been reported to improve endothelial function (EF) and
blood pressure (BP). However, most studies only assess large-vessel EF with little research on the
microvasculature. Thus, the aim of the present pilot study is to examine NO3− supplementation on
microvascular and large-vessel EF and BP. Twenty older adults (63 ± 6 years) were randomized to
a beetroot juice (BRJ) or placebo (PLA) group for 28 (±7) days and attended three laboratory visitations.
Across visitations, blood pressure, microvascular function and large-vessel EF were assessed by laser
Doppler imaging (LDI) with iontophoresis of vasoactive substances and flow-mediated dilatation
(FMD), respectively. Plasma NO3−concentrations, BP and the presence of NO3− reducing bacteria
were also assessed. Plasma NO3− increased following two weeks of BRJ supplementation (p = 0.04)
along with a concomitant decrease in systolic and diastolic BP of approximately −6 mmHg and
−4 mmHg, respectively (p = 0.04; p = 0.01, respectively). BP remained unchanged in the PLA
group. There were no significant differences in endothelium-dependent or endothelium-independent
microvascular responses between groups. FMD increased by 1.5% following two weeks of BRJ
(p = 0.04), with only a minimal (0.1%) change for the PLA group. In conclusion, this pilot study
demonstrated that medium-term BRJ ingestion potentially improves SBP, DBP and large-vessel EF
in healthy older adults. The improvements observed in the present study are likely to be greater in
populations presenting with endothelial dysfunction. Thus, further prospective studies are warranted
in individuals at greater risk for cardiovascular disease.
Keywords: dietary nitrate; endothelial dysfunction; endothelial function; large-vessels; microvessels;
blood pressure
1. Introduction
The endothelium is the inner most lining of the vasculature and plays a pivotal role in regulating
vascular tone via the release of several vasoactive factors [1]. One such factor is nitric oxide (NO),
which is a potent vasodilator that is important for maintaining vascular homeostasis [2]. Endothelial
dysfunction (ED) is characterized by a reduction in NO bioavailability and can increase cardiovascular
disease (CVD) risk, particularly in older individuals [3,4].
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Vegetables such as beetroot and spinach contain high levels of nitrate (NO3−) and when consumed,
they can increase NO bioavailability independently of the endothelium [5]. When ingested, dietary
NO3− is partially absorbed into the circulation and is later taken up by the salivary glands. Within the
oral cavity NO3− becomes 10- to 20-fold more concentrated in the saliva [6]. Further, salivary NO3−
is reduced to nitrite (NO2−) by commensal facultative anaerobic bacteria, located on the posterior
region of the tongue. After swallowing, most of the salivary NO2− is converted to NO in the acidic
conditions of the stomach; however, a small percentage is transported into the circulation. Once in
the circulation, NO2− is converted to NO through enzymatic and non-enzymatic reactions [7–11].
This endothelium-independent production of NO is commonly described as the entero-salivary
NO3−–NO2−–NO pathway [12]. A growing body of literature identifies dietary NO3− as an exogenous
source of NO, which has the capacity to improve endothelial function (EF) in individuals at risk of
CVD [13].
A prospective study (over 14 years) in a cohort of older adults, reported that a diet low in
NO3− rich vegetables was correlated with the prevalence of CVD mortality [14], this conclusion is
also in line with previous findings from the same research group [15]. Furthermore, the high NO3−
content of a Mediterranean and Japanese diet has been suggested to be associated with significant
blood pressure (BP) improvements [16,17]. Diets, which are naturally rich in NO3−, supplements
such as beetroot juice (BRJ), have also been demonstrated to have beneficial effects on BP [9,18–25].
Although these discoveries support the cardioprotective features of dietary NO3−, little is known
about the underlying mechanisms. In humans, EF is commonly assessed in conduit arteries using
flow-mediated dilatation (FMD), which measures the endothelium-dependent dilatory response to
reactive hyperaemia. In a large cohort of 68 hypertensive patients, FMD responses were significantly
improved following four weeks of daily BRJ consumption [19]. Furthermore, both systolic BP (SBP)
and diastolic BP (DBP) were reduced following one week of the intervention and were sustained
throughout the four-week supplementation period. Interestingly, there is limited research available that
has investigated the effect of NO3− supplementation on microvascular EF, despite the microvasculature
being the primary regulator of systemic vascular resistance (SVR) and encompassing a larger surface
area than the large vessels [26]. Moreover, microvascular ED is believed to precede ED in the larger
blood vessels [27]. However, due to the heterogeneity of the endothelium, no clear associations can be
made between vascular beds [28,29]. Therefore, it is important to understand the underlying principles
of microvascular EF.
Gilchrist et al. examined the effects of a two-week BRJ intervention on microvascular function,
large-vessel function and BP in individuals diagnosed with type II diabetes (T2D) [30]. Large-vessel
function was assessed using FMD and nitroglycerine-mediated dilatation (endothelium-independent),
while microvascular function was measured using laser Doppler imaging (LDI) with iontophoresis of
endothelium-dependent (acetylcholine (ACh)) and endothelium-independent (sodium nitroprusside
(SNP)) agonists [31]. Contrary to Gilchrist and colleagues’ hypothesis, the intervention did not
result in any significant improvements in vascular function or BP. The authors concluded that
subjects had irreversibly diminished vascular reactivity, due to having multiple risk factors for CVD.
Nonetheless, a longer intervention of six weeks has been shown to improve FMD and reduce SBP in
hypercholesterolemic patients, although no microvascular assessment was performed in this study [18].
Therefore, the present pilot study aims to examine the effect of BRJ supplementation
on microvascular function, large-vessel EF and BP in older adults over a four-week period.
We hypothesized that four weeks of daily supplementation with NO3− rich BRJ will increase NO
bioavailability, along with concomitant improvements in vascular function and BP.
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2. Materials and Methods
2.1. Participants
Thirty-seven healthy older adults were recruited and assessed for eligibility by e-mail, flyers and
advertisements (Figure 1). Participants were allocated to each group using stratified randomization
based on age (±3 years) and gender to ensure similarities between both arms. From the sample,
16 people did not reply to the invitation, one person was excluded on medical grounds. Therefore,
20 healthy older adults (age: 63 ± 6 years) participated in the present study. Due to personal reasons,
two individuals withdrew from the study following a week of their intervention. Participants were
briefed on the nature and the purpose of the investigation before written consent was taken along with
a short demographic questionnaire to ensure that they satisfied the study criteria.
To avoid the effects of the menstrual cycle, only men and post-menopausal women aged 55
or older were recruited for the study. Exclusion criteria included any history of acute coronary
syndrome or established CVD, use of antihypertensive medication, chronic diseases or acute illnesses,
highly trained/active individuals, diets rich in green leafy vegetables and habitual use of antibacterial
mouthwash. All experimental procedures were performed in accordance with the ethical standards of
the Declaration of Helsinki and approved by the institutional ethics committee (S02-16/17).
Figure 1. Consolidated standards of reporting trials (CONSORT) flowchart of study. BP = blood
pressure; BRJ = beetroot juice; NO3− = nitrate and PLA = placebo.
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2.2. Experimental Design
A randomized placebo-controlled trial utilizing a parallel study design was used to test the
hypothesis. Those assessing the outcomes were blinded to the conditions and participants were
never told which treatment they were allocated to, only that both drinks had health benefits. For the
duration of the study, all participants were required to attend three laboratory visits, separated by
14 (±7) days. All visits were performed in a thermoregulated laboratory (21–22 ◦C), which started
between the hours of 07:30–09:00 am and lasted approximately 2 h. Participants arrived following
a 12-h fast and were asked to refrain from caffeine. They were also instructed to avoid strenuous
exercise 24 h prior to testing. Lastly, participants were asked to complete a three-day food diary and
the seven-day international physical activity questionnaire (IPAQ) [32] before attending the laboratory
sessions. Over the period of the study, all participants were asked to maintain their usual diet and
physical activity levels.
During each visit, anthropometric data was collected prior to any other assessments,
which included height, body mass, body mass index (BMI) and body fat percentage (TANITA
C-300; Tanita Ltd, Japan). Venous blood samples were collected into ethylenediaminetetraacetic acid
(EDTA) collection tubes and were centrifuged immediately. The plasma was separated into 500 µL
aliquots before being transferred to a −80 ◦C freezer for later analysis. Following the blood sample,
a tongue scrape sample, containing potential nitrate reducing bacteria, was collected from the posterior
region of the tongue. Samples were transferred into a NO3− medium and immediately incubated.
Subsequently, participants were asked to lie down for 10 min before three separate automated BP
measurements were taken (separated by 2 min) and the mean value was recorded. Whilst remaining in
a recumbent position, vascular function of the small and large blood vessels was assessed (separated
by 15 min).
2.3. Drink Intervention
Daily consumption of the active or placebo (PLA) treatment was instructed for the duration
of their enrolment. The active treatment was a 70 mL NO3− rich BRJ drink (Beet-It Sport Shot 400;
James White Ltd, Ashbocking, UK), providing approximately 400 mg of NO3− each day. For the
PLA group, prune juice (Sunsweet Growers Inc., Kingston upon Hull, UK) was selected because of
the negligible NO3− levels (<0.01 mM) [33] and similar consistency and colour to BRJ. Additionally,
carbohydrate and fibre content of both treatments have been reported to be similar [33]. All participants
were asked to consume their allocated drink in the morning and to keep it consistent for the duration
of the study, with the exception of testing days.
2.4. Dietary NO3− and NO2− Intake
The NO3− and NO2− content was determined by a database containing NO3− and NO2− values
from 7703 foods and beverage records from 432 publications [34]. To develop the most accurate and
appropriate values in terms of the study population location, a similar method previously described [35]
was used with priority given to: 1) The UK/European countries from 1990 to present; 2) the UK/European
countries from 1960–1989; 3) countries with predominately Western diets (Australia, U.S and Canada)
from 1990 to present; 4) countries with predominately Western diets from 1960–1989 and 5) countries
with predominately non-Western diets. The cut-off dates were chosen to account for changes in
laboratory methods, food preservation techniques and manufacturing technologies (the addition of
ascorbate during meat processing, added to reduce the formation of nitrosamines), and legislation
regulating the amounts of NO3− and NO2− used in the curing process created significant reductions in
food and beverages [36,37].
NO3− and NO2− intake was calculated by multiplying the food or beverage item consumed (grams
per day) as the weighted mean value of that item identified using the multistep process mentioned
above. Weighted mean was selected as some mean values were adversely affected by extreme values.
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If a NO3− or NO2− value was unattainable a value of 0 mg/g was assigned to the food or beverage
item. Cooking methods such as baked, blanched, boiled, broiled, cooked, fried, microwaved, raw and
steamed were reported when relevant and available.
If a food or beverage item’s serving amount was missing from the recall data, the recommended
serving size amount was calculated using summary estimates (in grams) as defined by standard
serving sizes in nutritional analysis software [38,39]. In the case of multicomponent foods (e.g., pizza,
juices, salad mix, soup and curries), nutrient values were determined by calculating the NO3− and
NO2− content of all ingredients contained in the recipe list, or in the case of commercial products,
looking at the ingredients list or using the recipe reproduction [40]. Recipes were selected from reliable
and common online kitchen resource materials. Total NO3− and NO2− (mg/day) were determined by
calculating the sum of daily NO3− and NO2− values.
2.5. Presence of NO3− Bacteria
A tongue scraping was collected from each participant during their first visit following an oral
examination to ensure there were no signs of any mouth infections. The scrapings were performed
using a disposable acrylic spatula from the posterior region of the tongue and were collected into
sterile disposable pipette (Fisher Scientific, Cat. No. 13489108). Samples were transferred into 6 mL
of NO3− rich medium (Ingredients per litre of deionized water: Pancreatic Digest of Gelatin 5.0 g;
Beef Extract: 3.0 g; Potassium Nitrate: 1.00 g; Hardy Diagnostics, Cat. No. K42) and incubated for 54 h
at 37 ◦C, 95% humidity and 5% CO2. To ensure a similar inoculum size, the weight gain of the broth
was kept constant at approximately 10 µg.
Following incubation, 1 mL of the NO3− broth was extracted through a Puradisc 25
Polyethersulfone 0.2 µm sterilizing grade filter (Fisher Scientific, Cat. No. 6780-2502) to ensure
that any bacteria were eliminated. Content of the syringe was then emptied into separate 500 µL
aliquots and immediately frozen at –80 ◦C for later analysis of NO3−. The levels of NO3− in the
medium were analysed before and after incubation. Reductions in NO3− levels are expressed as
a percentage change (∆NO3−%), in order to determine the presence of NO3− reducing bacteria. All the
NO3− analyses are described in more detail in Section 2.8.
2.6. Microvascular Function
Iontophoresis administration of ACh (Miochol-E, Novartis, UK) and SNP (Nitroprussiat Fides,
Rottapharm SL, Spain) was performed using an iontophoresis controller (MIC-Ie, Moor Instruments Ltd,
UK) in order to assess cutaneous endothelium-dependent and endothelium-independent vasodilation,
respectively. Perfusion changes on the anterior surface of the forearm in response to the delivery of
both vasoactive drugs were assessed using LDI, which measures blood flux (AU). The full protocol that
was used for this study has been described in detail previously [41]. In summary, one baseline scan was
performed before a series of ten scans with an iontophoresis charge of 30 µA was delivered to administer
1% ACh and 1% SNP. ACh and SNP drugs were diluted with 0.9% saline and delivered into the skin
via an anode and cathode internal electrode Perspex chamber (Ø22 mm; ION 6, Moor Instruments Ltd,
UK), respectively. Following ten scans with iontophoresis, two further recovery scans were performed
without the delivery of the vasoactive drugs.
The exposure-time-response protocol took approximately 15–20 min and all of the scans were
performed in natural lighting conditions, with most of the ambient lighting restricted. Additionally,
the settings of the laser Doppler imager (moorLDI2-IR, Moor Instruments, Axminster, Devon, UK) were
kept consistent for all scans. Measurements of perfusion were carried out offline using the moorLDI
Review V6.1 software and results are presented as a percentage change in perfusion from baseline
( Peak Flux−Baseline FluxBaseline Flux ×100 = ACh% or SNP%).
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2.7. Large-Vessel Endothelial Function
The FMD procedure is a non-invasive technique that is commonly used on the brachial artery
as an assessment of global large-vessel EF. Several published guidelines are available for this
technique [42–44], however the present study used Sandoo and Kitas’ protocol [41]. Briefly, a 2 min
baseline ultrasound scan of the brachial artery was followed by 5 min of arterial occlusion, achieved by
inflating a BP cuff that was placed around the wrist to 220 mmHg. After a 5 min period of ischemia,
the BP cuff was deflated rapidly, and a further 3 min scan of the artery was performed.
A Siemens Acuson X300 Ultrasound scanner was used with a multifrequency linear-array vascular
probe set at 7.3 MHz (Siemens PLC, Camberley, UK) to perform the FMD procedure. B-mode images
were captured at 15 frames per second to record a 120 s baseline and a 210 s clip following 5 min
of occlusion. To capture the initial reactive hyperaemic response to the deflation of the BP cuff,
the recording was initiated 30 s before cuff release; therefore, only 180 s was used for the analysis.
Images were analysed offline using an automated edge detection software (Brachial Analyser, Medical
Imaging Applications, USA). The Brachial Analyser software is capable of detecting the peak of the
R-wave, therefore, this inbuilt feature was used to include only the images at the peak of the R-wave.
Frames that did not meet the recommended quality standard (confidence threshold <70%) were rejected.
From the frames that were accepted, the change in diameter from baseline to peak was calculated as
follows, Peak Diameter−Baseline DiameterBaseline Diameter ×100 = FMD%. To account for the differences in baseline diameter,
all the data was allometrically scaled as per the Atkinson and Batterham guidelines [45]. The coefficient
of variation for the sonographer (DTJ) was reported as 8.5%
2.8. Analysis of NO3− Concentration
Whole venous blood samples were collected into EDTA collection tubes following a 12 h fast.
Samples were immediately stored on ice or placed in a pre-chilled (4 ◦C) centrifuge. Once samples were
centrifuged, 500 µL plasma aliquots were instantly stored at −80 ◦C. Prior to analysis, plasma samples
were thawed and centrifuged again through an Amicon 30 kDa molecular weight filter to reduce
protein content [46]. Similarly, the sample of NO3− medium, for determining the presence of bacteria
(Section 2.5), was also filtered in the same manner. Analysis of NO3− concentrations was performed
using the Griess Reagent system as previously described by Miranda et al. [47]. Blood samples were
analysed at baseline, week 2 (WK2) and week 4 (WK4), whilst medium samples were only analysed at
baseline. Medium samples were diluted accordingly to ensure the NO3− values would fall within the
standard range. Sodium nitrate was used for standard quantification and the results were expressed in
micromoles per litre (µM). The coefficients of variation (n = 35, in duplicate) of the methods were 2.9%
to intra-assay and 4.0% to inter-assay.
2.9. Statistical Analysis
Per-protocol analysis was utilized for the present study. The assumption of normality, homogeneity
of variances and sphericity were examined with the Shapiro–Wilk, Levene’s and Mauchly tests,
respectively. For the primary and secondary outcomes, the change in each parameter was compared
between placebo and dietary nitrate arms by an unpaired Student t-test. Changes in parameters over
time were compared by repeated measures analysis of variance (ANOVA) with Bonferroni post hoc
tests (to account for multiple comparisons) and unpaired Student t-test for comparisons between
groups. The level for statistical significance taken was p < 0.05 for all analyses. If groups were different
at baseline for any of the dependent variables, an analysis of covariance (ANCOVA) was used to test
for differences between groups at two weeks and four weeks with baseline values being included as
the covariate. Results for all normally distributed data are presented as mean ± standard deviation
(SD). Data that were skewed were log transformed, however the median and interquartile range (IQR)
of the raw data are presented. All analyses were performed using a commercially available statistical
package (IBM SPSS Statistics version 22 for Windows, Chicago, IL, USA).
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3. Results
A total of 18 participants completed all three study visits between January 2017 to December 2018.
According to verbal confirmation, both interventions were well tolerated for the duration of the study.
No serious adverse events were experienced, however common side effect such as beeturia and faecal
discolouration were reported. Baseline demographic characteristics were similar for both treatment
allocations (Table 1). None of the participants had any uncontrolled conditions and were considered to
be healthy individuals.
Table 1. Baseline characteristics stratified by treatment allocation.
Treatment Allocation BRJ PLA Significance
Demographics
n 11 7
Age (y) 65 ± 8 61 ± 5 0.34
Height (cm) 167.4 ± 9.5 165.3 ± 6.2 0.62
Weight (kg) 73.2 ± 16.6 73.3 ± 8.0 0.99
BMI (kg/m2) 26.2 ± 6.3 26.9 ± 2.1 0.80
Body Fat (%) 30.7 ± 10.5 33.8 ± 7.7 0.51
Dietary Intake
NO3− 151.8 ± 77.8 185.3 ± 75.7 0.78
NO2− 7.4 ± 3.8 5.8 ± 1.9 0.49
Clinical BP
SBP 129 ± 12 124 ± 14 0.46
DBP 75 ± 8 79 ± 3 0.23
Data are presented as mean ± SD. p-values shown in the last column for an unpaired Student t-test. BMI = body
mass index; BRJ = beetroot juice; DBP = diastolic blood pressure; NO3− = nitrate; NO2− = nitrite; PLA = placebo
and SBP = systolic blood pressure.
3.1. Plasma Nitrate Concentrations
Plasma samples were analysed for 12 individuals (6 BRJ; 6 PLA), due to insufficient volumes
from the remaining six participants (Figure 2). Across the duration of the study, NO3− levels were
highest in the BRJ group following two weeks of supplementation but declined slightly from WK2 to
WK4. Mean plasma NO3− concentrations of the BRJ group increased from 34 ± 8 µM to 132 ± 83 µM
following two weeks (p = 0.04), with concentrations measuring at 78 ± 41 µM at four weeks (p = 0.60).
Furthermore, NO3− levels were significantly greater compared to PLA treatment at WK2 and WK4
(p = 0.02; p = 0.03, respectively). There were no significant changes in plasma NO3− concentration
within the PLA group.
3.2. Resting Blood Pressure
Following two weeks of BRJ ingestion, SBP reduced by −6 ± 7 mmHg and DBP by −4 ± 3 mmHg
(p = 0.04; p = 0.01, respectively). However, from WK2 to WK4, SBP increased by 2 ± 7 mmHg (p = 1.00)
and DBP by 2 ± 4 mmHg (p = 0.49). Over the four-week course of the BRJ treatment, SBP reduced
by −4 ± 10 mmHg (p = 0.67) and DBP by −2 ± 6 mmHg (p = 0.75). Within the PLA treatment group,
SBP reduced by −1 ± 10 mmHg following two weeks and DBP by 0 ± 5 (p = 1.00). From WK2 to
WK4, SBP was further reduced by −4 ± 7 mmHg (p = 0.70) and DBP by 0 ± 3 mmHg (p = 1.00).
Over the four-week course of the PLA treatment, SBP reduced by −5 ± 6 mmHg (p = 0.17) and DBP by
−1 ± 4 mmHg (p = 1.00). None of the BP changes for PLA treatment reached statistical significance.
Additionally, no significant differences were observed between the groups at any time point (Figure 3).
Similarly, the changes in BP were not significant between the two groups after two and four weeks
(Table 2).
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Figure 2. The effects of four weeks of BRJ consumption or PLA on plasma nitrate. Beetroot juice
consumption increases plasma nitrate in healthy older adults. Data are expressed as mean ± SD.
* Significance shown for comparisons within treatment allocations of the change between baseline,
week 2 and week 4, p < 0.05 for Bonferroni post hoc test. Significance shown for comparisons between
treatment allocations for an unpaired Student t-test, p < 0.05. BRJ = beetroot juice; PLA = placebo.
Figure 3. The effects of four weeks of BRJ consumption or PLA on BP. Beetroot juice consumption
reduces (A) SBP and (B) DBP in healthy older adults. Data are expressed as mean ± SD. * Significance
shown for comparisons within treatment allocations of the change between baseline, week 2 and
week 4, p < 0.05 for a Bonferroni post hoc test. BRJ = beetroot juice; DBP = diastolic blood pressure;
PLA = placebo and SBP = systolic blood pressure.
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Table 2. Changes in vascular outcomes during the intervention.
BRJ PLA P (Comparison between BRJ and PLA)
Baseline Week 2 Week 4 ∆
Week 2 − Baseline
∆
Week 4 −Week 2
∆
Week 4 − Baseline
Baseline Week 2 Week 4 ∆
Week 2 − Baseline
∆
Week 4 −Week 2
∆
Week 4 − Baseline
∆
Week 2 − Baseline
∆
Week 4 −Week 2
∆














11 −1 ± 10 −4 ± 7 −5 ± 6 0.23 0.12 0.84
DBP









































































2.63 0.07 ± 0.83 0.46 ± 0.33 0.54 ± 0.97 0.10 0.34 0.18
Data are presented as mean ± SD. An unpaired Student t-test was used to evaluate differences in changes (∆) between the two groups. ACh = acetylcholine; BRJ = beetroot juice;
DBP = diastolic blood pressure; FMD = flow-mediated dilatation; PLA = placebo; SBP = systolic blood pressure and SNP = sodium nitroprusside.
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3.3. Dietary NO3− and NO2− Intake
Analysis of the three-day self-report food diary was performed in order to quantify the NO3− and
NO2− intake at baseline, before their second visitation and before their final visitation (Table 3). At each
time-point, the intake of NO3− and NO2− did not significantly differ between groups. Furthermore,
no difference was observed over the four weeks within the BRJ and PLA groups.
Table 3. Quantification of the amount of NO3− and NO2−, measured with a three-day self-report
food diary.
Treatment Allocation BRJ PLA Significance
NO3− (mg)
Baseline 151.8 ± 77.8 185.3 ± 75.7 1.00
WK2 182.5 ± 72.4 200.2 ± 63.2 0.66
WK4 195.4 ± 66.9 190.4 ± 113.6 0.47
NO2− (mg)
Baseline 7.4 ± 3.8 5.8 ± 1.9 0.12
WK2 6.2 ± 4.0 8.2 ± 2.9 0.43
WK4 8.1 ± 4.4 5.1 ± 2.3 0.07
Data are presented as mean ± SD. p-values shown in the last column for an unpaired Student t-test. BRJ = beetroot
juice; NO3− = nitrate; NO2− = nitrite; PLA = placebo; WK2 = week 2 and WK4 = week 4.
3.4. Presence of NO3− Reducing Bacteria
Twelve participants were included for the oral microbiome assessment (6 BRJ; 6 PLA).
This assessment was used to determine the presence of NO3− reducing bacteria. Every participant
who was included for this assessment demonstrated the capacity to reduce NO3−. Following 54 h in
incubation, the tongue scrape samples from each participant successfully reduced all of the NO3− in the
broth medium, meaning a 100% reduction of the available NO3− substrate. These results confirmed the
presence of NO3− reducing bacteria in the oral cavity of the 12 participants included for this analysis.
3.5. Microvascular Function
Blood flux was quantified by calculating the median rather than the mean for each region of interest.
This is due to the fact the laser Doppler imaging data will rarely have Gaussian distribution [48]. The flux
responses to ACh and SNP were not normally distributed for any of the laboratory visits, therefore
log-transformed data was used to test for differences. However, the results are presented using raw data
as percentage changes in flux with IQR (Figure 4). Contrary to our hypothesis, no significant differences
in endothelium-dependent (ACh) or endothelium-independent (SNP) microvascular responses were
observed over the three visitations.
As expected, flux values increased in response to the iontophoresis of ACh for both groups.
During the baseline visit, the median responses were measured at 380.0% (IQR: 743.6%) for the BRJ
group and 44.3% (IQR: 133.3) for the PLA (p = 0.03). Significant differences between groups were
reported at baseline; therefore, these values were used as a covariate in ANCOVA analysis to test for
difference between groups at WK2 and WK4. Median responses at WK2 were 234.9% (IQR: 473.8%)
for BRJ group and 117.8% (IQR: 141.8%) for the PLA group (p = 0.75). Furthermore, no significant
differences between groups was observed at WK4, with the BRJ response measured at 108.1% (IQR:
665.45%) and PLA response measured at 59.1% (IQR: 130.94%; p = 0.42). Similarly, the changes in ACh
were not significant between the two groups after two and four weeks (Table 2).
As expected, flux values increased in response to the iontophoresis of SNP for both groups. During
the baseline visit, the median responses were measured at 510.0% (IQR: 864.5%) for the BRJ group and
112.3% (IQR: 131.0) for the PLA (p = 0.15). Median responses at WK2 were 260% (IQR: 906.4%) for BRJ
group and 73.1% (IQR: 223.3%) for the PLA group (p = 0.43). Furthermore, no significant differences
between groups was observed at WK4, with the BRJ response measured at 33.4% (IQR: 830.8%) and
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PLA response measured at 107.0% (IQR: 171.9%; p = 0.80). Similarly, the changes in SNP were not
significant between the two groups after two and four weeks (Table 2).
Figure 4. The effect of treatments on laser Doppler imaging (LDI) with iontophoresis is over four weeks
(n = 18). Log-transformed data was used for all analyses, as the untransformed data was not normally
distributed. Untransformed data expressed as median (IQR). ACh = acetylcholine; LDI = laser Doppler
imaging; IQR = interquartile range and SNP = sodium nitroprusside.
3.6. Large-Vessel Endothelial Function
Data loss occurred for three participants, therefore only 15 participants (9 BRJ; 6 PLA) were
included for the main FMD analysis. FMD responses increased from baseline to WK2 for the BRJ
treatment and the improvements were sustained until WK4. At baseline, endothelium-dependent
vasodilation was 5.6% ± 1.8% in the BRJ group and for the PLA group it was 6.4% ± 2.5% (p = 0.49).
Within the BRJ group, FMD values increased by 1.5% ± 1.8% at WK2 (p = 0.04), however values only
increased by 0.1% ± 0.8% in the PLA groups (p = 0.84). After four weeks, FMD values increased by
1.5% ± 1.5% for the BRJ treatment (p = 0.01). The PLA group failed to reach any significance after
four weeks, although a small improvement of 0.5% ± 1.0% was reported (p = 0.23). Further to this,
no main effect between groups was found at WK2 (p = 0.58) or WK4 (p = 0.85; Figure 5A). Similarly,
the changes in FMD were not significant between the two groups after two and four weeks (Table 2).
Using appropriate allometric scaling methods on the data did not change any of the outcomes; however,
corrected data is presented in Figure 5B.
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Figure 5. The effects of four weeks of BRJ consumption or PLA on FMD. Beetroot juice consumption
increases FMD responses in healthy older adults. Both (A) uncorrected and (B) allometrically scaled
data are expressed as mean ± SD and individual data for uncorrected data. * Significance shown
for comparisons within treatment allocations of the change between baseline, week 2 and week 4,
p < 0.05 for the Bonferroni post hoc test. BRJ = beetroot juice; FMD = flow-mediated dilatation and
PLA = placebo.
4. Discussion
The findings from the present pilot study indicate that medium-term BRJ supplementation could
potentially improve large-vessel EF and BP in healthy older adults. Despite our findings showing no
main effect between groups, significant improvements in both SBP and DBP were reported within the
BRJ group after two weeks. However, the changes in BP were not significantly different to BP changes
in the PLA group. After four weeks, SBP and DBP values remained lower than baseline within the
BRJ group, but were no longer significant. Interestingly, a large reduction of −5 ± 6 mmHg in SBP
was observed in the PLA group following four weeks and could potentially mask any between group
effects. Although the exact cause of these improvements was unknown, we concluded that they could
be due to the increase in IPAQ scores, which were not observed in the BRJ group. Alternatively, it has
been proposed that on average systolic and diastolic BP reduce by 15 mmHg and 7 mmHg respectively
by the third visit with a physician [49]. However, given that both groups would likely experience this
effect, the magnitude of BP change in BRJ is likely to be mediated by the increased NO3− levels from
the BRJ. Contrary to our hypothesis, the present pilot study observed no changes in microvascular
function in response to the intervention. This null finding cannot be explained by non-responders as
we demonstrated that participants had elevated plasma NO3− levels and a full capacity to convert the
NO3− within the oral microbiome.
A vast amount of research has demonstrated the significance of nutritional therapy for
cardiovascular health, particularly for high BP [43,44]. In recent years, dietary NO3− is one nutraceutical
that has been identified as a treatment for hypertension (average reductions: SBP; −4.4 mmHg and DBP;
−1.1 mmHg) [50]. Aside from the present pilot study, only a few have tested medium-term interventions
on EF and BP in humans (≥4 weeks) [18,19]. According to a comprehensive review by Carlström et
al., this therapeutic effect is achieved through several mechanisms [51]. The evidence implies that
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improvements in EF were the primary explanation for these reductions. Indeed, exogenous sources
of NO have been shown to induce vasodilation, which consequently reduces SVR [52]. Interestingly,
these vascular responses to dietary NO3− consumption occur shortly after ingestion and coincide with
BP reductions. In support of this statement, Bondonno et al. demonstrated significant improvements
in FMD responses 2 h post NO3− ingestion, which were also accompanied by reductions in SBP.
To date, the longest intervention performed in humans is a six-week study, in hypercholesterolemic
individuals [18]. The authors reported that over the duration of the study, FMD responses improved
by 4% and both SBP and DBP were reduced (−4.1 mmHg and −1.5 mmHg, respectively). Further
support for medium-term supplementation was published by Kapil et al. in 2015. They reported a 20%
improvement in FMD responses following four weeks of BRJ supplementation in a hypertensive cohort,
which was accompanied by reductions in SBP and DBP (−7.7 mmHg and−2.4 mmHg, respectively) [19].
Similarly, the present pilot study found improvements of 27% in FMD responses and reductions
of −4.1 mmHg and −2.1 mmHg in SBP and DBP, respectively. Despite our pilot data not showing
a significant effect between the groups, collectively, these positive findings imply that medium-term
use of NO3− supplements can reduce BP and improve EF of the large blood vessels. However, despite
the microvasculature being the primary regulator of SVR [53], only a few studies have investigated the
short or medium-term use of dietary NO3− on microvascular function.
Contrary to our hypothesis, four weeks of NO3− supplementation did not lead to significant
changes in endothelium-dependent or endothelium-independent microvascular reactivity. A potential
reason for this null finding could be explained by the pharmacologically vasoactive factors that were
administered. Neither, ACh or SNP stimulates the conversion of NO2− into NO, similar to what happens
under the ischemic conditions of the FMD procedure. However, Wong et al. stimulated microvascular
vasodilation using reactive hyperaemia and found that three days of BRJ supplementation did not
alter cutaneous vascular reactivity [54]. The authors proposed that cutaneous reactive hyperaemia
is not NO mediated and is rather to be largely dependent on cutaneous sensory-nerve and/or
calcium activated potassium (BKCa) channels [55]. It should be noted that this group used laser
Doppler flowmetry to measure cutaneous blood flux, which only measures perfusion at a single point.
Importantly, laser Doppler imaging scans a larger region of interest and thereby accounts for the spatial
heterogeneity of skin blood flow [56]. Therefore, further research is warranted in order to investigate
the effects of NO3− supplements on the microcirculation.
The participants for the present pilot study were recruited from a healthy aging population and
most of them showed no signs of hypertension. Although significant improvements in large-vessel EF
and BP were observed after two weeks within the BRJ group, it was not expected for improvements to
continue indefinitely due to the good health of the participants. However, the changes in plasma NO3−
levels corresponded with the changes in BP, thus when plasma NO3− levels decreased from two weeks
to four weeks, BP increased. Therefore, an alternative reason why improvements were not sustained
for the duration of the study could be explained by the reductions in circulating NO3−. The exact
cause of the diminished NO3− availability is not known. Some authors believe that NO3− and NO2−
clearance is upregulated with prolonged exposure [57], however, compliance to this intervention was
only confirmed verbally, therefore we are unsure if every participant adhered to their allocated drinks.
Limitations
A limitation of the present pilot study was the small sample size, due to difficulty with recruitment.
A-priori sample size calculation was not performed and therefore we are unable to confirm whether
the findings are adequately powered and the result should be interpreted with caution. Additionally,
as previously mentioned, compliance to the intervention was only confirmed verbally at the end of
the trial; but biological markers did support this declaration to an extent. Although plasma NO3−
levels were measured, we did not have the facilities to analyse NO2− concentrations. Previous finding
suggests that significant increases in plasma NO2− occur alongside increases in plasma NO3− in elderly
people with T2D [30]. Unfortunately, we were unable to analyse plasma NO3− nor NO3− reducing
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bacteria for all our participants, but the available data suggests that we did not recruit non-responders.
Furthermore, it should be noted that the 12 participants who were included for these assessments
were not necessarily the same individuals. The large variation in microvascular flux between groups
at baseline was also a limitation of the present study. While we accounted for this difference during
analysis of the follow-up visits, we are unclear about the exact reason for this difference.
5. Conclusions
In conclusion, this pilot study demonstrated that medium-term BRJ ingestion potentially improves
SBP, DBP and large-vessel EF in healthy older adults. These changes corresponded to the changes
in plasma NO3− levels. Although no changes in microvascular function were observed, further
prospective studies examining the long-term impact of NO3− supplementation on this vascular bed in
patient populations at risk of CVD are warranted.
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